抗TNFα治疗因血液检测异常停药及替代监测策略的成本效益
基于BADBIR注册的回顾性队列研究纳入8819例银屑病患者,评估抗TNFα治疗因监测血液检测异常而停药的发生率与风险因素。结果显示停药率较低(5.85/1000人年),延长监测间隔具成本效益。
要点
- 抗TNFα治疗首年后因血液检测异常停药率较低。
- 高龄、糖尿病和肝病与停药风险增加相关。
- 延长监测间隔比3或6个月监测更具成本效益。
核心结论
- 抗TNFα治疗首年后因监测血液检测异常而停药不常见,延长监测间隔具成本效益。
研究设计与样本
- 基于BADBIR注册的次级医疗回顾性队列研究,纳入至少中度银屑病且首次使用抗TNFα治疗的患者8819例。
主要发现
- 治疗首年内停药64例,发生率8.62(95%CI 6.74-11.01)/1000人年;首年后停药61例,发生率3.44(95%CI 2.67-4.42)/1000人年。
- 年龄增长、糖尿病和肝病与停药风险增加相关,调整风险比分别为1.02(95%CI 1.01-1.04)、1.68(95%CI 1.00-2.81)和2.27(95%CI 1.26-4.07)。
临床怎么用
- 研究结果为专业学会制定指南提供证据,以减少患者监测负担和医疗成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no evidence base to support the use of 6-monthly monitoring blood tests for the early detection of liver, blood and renal toxicity during established anti-tumour necrosis factor alpha (TNFα) treatment. OBJECTIVES: To evaluate the incidence and risk factors of anti-TNFα treatment cessation owing to liver, blood and renal side-effects, and to estimate the cost-effectiveness of alternate intervals between monitoring blood tests. METHODS: A secondary care-based retrospective cohort study was performed. Data from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) were used. Patients with at least moderate psoriasis prescribed their first anti-TNFα treatment were included. Treatment discontinuation due to a monitoring blood test abnormality was the primary outcome. Patients were followed-up from start of treatment to the outcome of interest, drug discontinuation, death, 31 July 2021 or up to 5 years, whichever came first. The incidence rate (IR) and 95% confidence intervals (CIs) of anti-TNFα discontinuation with monitoring blood test abnormality was calculated. Multivariate Cox regression was used to examine the association between risk factors and outcome. A mathematical model evaluated costs and quality-adjusted life years (QALYs) associated with increasing the length of time between monitoring blood tests during anti-TNFα treatment. RESULTS: The cohort included 8819 participants [3710 (42.1%) female, mean (SD) age 44.76 (13.20) years] that contributed 25 058 person-years (PY) of follow-up and experienced 125 treatment discontinuations owing to a monitoring blood test abnormality at an IR of 5.85 (95% CI 4.91-6.97)/1000 PY. Of these, 64 and 61 discontinuations occurred within the first year and after the first year of treatment start, at IRs of 8.62 (95% CI 6.74-11.01) and 3.44 (95% CI 2.67-4.42)/1000 PY, respectively. Increasing age (in years), diabetes and liver disease were associated with anti-TNFα discontinuation after a monitoring blood test abnormality [adjusted hazard ratios of 1.02 (95% CI 1.01-1.04), 1.68 (95% CI 1.00-2.81) and 2.27 (95% CI 1.26-4.07), respectively]. Assuming a threshold of £20 000 per QALY gained, no monitoring was most cost-effective, but all extended periods were cost-effective vs. 3- or 6-monthly monitoring. CONCLUSIONS: Anti-TNFα drugs were uncommonly discontinued owing to abnormal monitoring blood tests after the first year of treatment. Extending the duration between monitoring blood tests was cost-effective. Our results produce evidence for specialist society guidance to reduce patient monitoring burden and healthcare costs.
引用
- Abhishek A, Stevenson MD, Nakafero G, et al. Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies. Br J Dermatol. 2024. PMID: 37931161. doi:10.1093/bjd/ljad430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。